Research by AB Science regarding masitinib, its flagship molecule, is aimed at providing innovative therapeutic solutions in three main areas of medicine: oncology, inflammatory diseases, and neurological disorders.
Key concepts underpinning this innovation include:
– Masitinib is a potent inhibitor of mast cell activity, cells that are important for orchestrating and maintaining the inflammatory cascade.
– Masitinib stimulates an innate immune response and induces changes in the tumor micrœnvironment, the benefit of which is to extend survival.
– Masitinib is a highly selective inhibitor of tyrosine kinases important in the pathogenesis of certain cancers.
The results of phase II clinical trials in all these areas of research are encouraging. If successful, this development program will provide patients with a new and less constraining therapeutic option; namely, an effective, well-tolerated oral treatment, often in rare indications with high unmet medical need
WHY DŒS AB SCIENCE’S BUSINESS MODEL CREATE VALUE?